Table 2 Clinical, laboratory and genetic characteristics of younger (< 60 years) and older (≥ 60 years) MDS patients
Characteristic | Total (n = 852) | Age < 60 years (n = 540) | Age ≥ 60 years (n = 312) | P-value |
|---|---|---|---|---|
Age (years)* | 56 (44–64) | 48 (37–55) | 61 (63–70) | |
Sex n (%) | < 0.0001 | |||
Male | 550 (64.6) | 325 (60.2) | 225 (72.1) | |
Female | 302 (35.4) | 215 (39.8) | 87 (27.9) | |
BM blasts (%)* | 2.5 (17) | 2 (0.5–6) | 4.5 (1–8) | < 0.0001 |
(Missing) | 1 | 1 | 0 | |
Hemoglobin (g/L)* | 79 (66–95) | 78 (65–96) | 79 (66–95) | 0.703 |
(Missing) | 0 | 0 | 0 | |
Platelets (× 109/L)* | 60 (31–119) | 59 (29–121) | 63 (35–117) | 0.260 |
(Missing) | 0 | 0 | 0 | |
ANC (× 109/L)* | 1. (0.7–2) | 1.1 (0.7–2) | 1.1 (1.6–2) | 0.930 |
(Missing) | 0 | 0 | 0 | |
IPSS-R karyotype | < 0.0001 | |||
Very good | 10 (1.2) | 4 (0.7) | 6 (1.9) | |
Good | 427 (50.1) | 261 (48.3) | 166 (53.2) | |
Intermediate | 186 (21.8) | 138 (25.6) | 48 (15.4) | |
Poor | 42 (4.9) | 32 (5.9) | 10 (3.2) | |
Very poor | 95 (11.2) | 50 (9.3) | 45 (14.4) | |
(Missing) | 92 | 55 | 37 | |
IPSS-R category | 0.332 | |||
Very low | 28 (3.3) | 19 (3.5) | 9 (2.9) | |
Low | 185 (21.7) | 118 (21.9) | 67 (21.5) | |
Intermediate | 241 (28.3) | 165 (30.6) | 76 (24.4) | |
High | 175 (20.5) | 105 (19.4) | 70 (22.4) | |
Very high | 131 (15.4) | 78 (14.4) | 53 (17.0) | |
(Missing) | 92 | 55 | 37 | |
IPSS-M category | 0.027 | |||
Very low | 21 (2.5) | 16 (3.0) | 5 (1.6) | |
Low | 138 (16.2) | 92 (17.0) | 46 (14.7) | |
Moderate low | 125 (14.7) | 81 (15.0) | 44 (14.1) | |
Moderate high | 113 (13.3) | 82 (15.2) | 31 (9.9) | |
High | 170 (20.0) | 108 (20.0) | 62 (19.9) | |
Very high | 192(22.5) | 106(19.4) | 87(27.9) | |
(Missing) | 93 | 55 | 37 | |
WHO 2016 subtypes | < 0.0001 | |||
MDS-SLD/MLD | 414 (48.6) | 295 (54.6) | 119 (38.1) | |
MDS-RS-SLD/MLD | 46 (5.4) | 24 (4.4) | 22 (7.0) | |
MDS-EB1/2 | 359 (42.1) | 195 (36.1) | 164 (52.5) | |
5q- syndrome | 12 (1.4) | 8 (1.5) | 4 (1.3) | |
Unclassified MDS | 21 (2.5) | 18 (3.3) | 3 (1.0) | |
(Missing) | 0 | 0 | 0 | |
Mutations | ||||
U2AF1 | 189 (22.2) | 141 (26.1) | 48 (15.4) | < 0.0001 |
ASXL1 | 157 (18.4) | 90 (16.7) | 67 (21.5) | 0.081 |
RUNX1 | 101 (11.9) | 51 (9.4) | 50 (16.0) | 0.004 |
SF3B1 | 92 (10.8) | 51 (9.4) | 41 (13.1) | 0.094 |
TP53 | 85 (10.0) | 41 (7.6) | 44 (14.1) | 0.002 |
DNMT3A | 70 (8.2) | 36 (6.7) | 34 (10.9) | 0.030 |
TET2 | 69 (8.1) | 32 (5.9) | 37 (11.9) | 0.002 |
TP53multihit | 53 (6.2) | 27 (5.0) | 26 (8.3) | 0.052 |
SRSF2 | 51 (6.0) | 16 (3.0) | 35 (11.2) | < 0.0001 |
BCOR | 47 (5.5) | 28 (5.2) | 19 (6.1) | 0.577 |
NRAS | 42 (4.9) | 26 (4.8) | 16 (5.1) | 0.839 |
SETBP1 | 39 (4.6) | 25 (4.6) | 14 (4.5) | 0.924 |
EZH2 | 32 (3.8) | 14 (2.6) | 18 (5.8) | 0.019 |
STAG2 | 32 (3.8) | 10 (1.9) | 22 (7.1) | < 0.0001 |
NPM1 | 30 (3.5) | 24 (4.4) | 6 (1.9) | 0.054 |
PTPN11 | 24 (2.8) | 13 (2.4) | 11 (3.5) | 0.342 |
PHF6 | 22 (2.6) | 14 (2.6) | 8 (2.6) | 0.980 |
KMT2D | 21 (2.5) | 13 (2.4) | 8 (2.6) | 0.885 |
ZRSR2 | 20(2.3) | 11(2.0) | 9 (2.9) | 0.432 |
DDX41 | 20(2.3) | 5(0.9) | 15 (4.8) | < 0.0001 |
IDH2 | 18(2.1) | 10(1.9) | 8 (2.6) | 0.486 |
KRAS | 18(2.1) | 12(2.2) | 6 (1.9) | 0.770 |
GATA2 | 18(2.1) | 13(2.4) | 5 (1.6) | 0.431 |
WT1 | 17(2.0) | 14(2.6) | 3 (1.0) | 0.101 |
JAK2 | 16(1.9) | 9(1.7) | 7 (2.2) | 0.550 |
ETV6 | 15(1.8) | 11(2.0) | 4 (1.3) | 0.420 |
CEBPA | 13 (1.5) | 7 (1.3) | 6 (1.9) | 0.472 |
FLT3 ITD/TKD | 14 (1.6) | 8 (1.5) | 6 (1.9) | 0.625 |
CBL | 12 (1.4) | 7 (1.3) | 5 (1.6) | 0.715 |
MPL | 12 (1.4) | 10 (1.9) | 2 (0.6) | 0.148 |
BCORL1 | 10 (1.2) | 6 (1.1) | 4 (1.3) | 0.823 |
FAT1 | 10 (1.2) | 7 (1.3) | 3 (1.0) | 0.660 |
CUX1 | 10 (1.2) | 9 (1.7) | 1 (0.3) | 0.079 |